ART Advanced Research Technologies to Present SoftScan at the Breast Course Symposium in Quebec City

MONTREAL, CANADA (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce its participation as a Bronze Sponsor and exhibitor in the 2008 edition of The Breast Course, to be held at the Fairmont Chateau Frontenac in Quebec City, Canada from April 13 to April 16, 2008. ART is an exhibitor at the event and will present its SoftScan® breast imaging device designed to improve the diagnosis and treatment of breast cancer, at its booth located in the Frontenac Room of the Fairmont Chateau Frontenac.

The course is a multidisciplinary event aiming to present the best practices and state-of-the-art products to breast professionals and brings together an international faculty of opinion leaders in breast cancer detection, intervention and therapy offering top-notch instruction to more than 350 participants from 26 countries.

"We are pleased to be present once again this year at The Breast Course symposium, which is now recognized worldwide as the premier educational event dealing with breast diseases and which gives us the opportunity to showcase our SoftScan system to an audience of breast care specialists and other participants from over 25 countries," said Sebastien Gignac, ART's President and CEO. "The SoftScan system, now approved for commercialization in Canada and Europe, offers another option to women and their physicians in instances where mammography is either ineffective or impractical to use, as well as the possibility to monitor the treatment of patients undergoing chemotherapy for breast cancer," he added.

About SoftScan®

The SoftScan® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, the SoftScan system emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2007, available on SEDAR (www.sedar.com).

Contacts: ART Advanced Research Technologies Inc. Jacques Bedard Chief Financial Officer 514-832-0777 [e-mail] www.art.ca